← brief for 2026-10-19 · Slowing decline

Key safety outcomes of SGLT2 inhibitors versus DPP-4 inhibitors in general and vulnerable participants with T2DM: A target trial emulation study.

Key takeaways

This study compared two diabetes drugs in 224,510 people. It looked at safety issues, especially in older or frail patients. The study shows a link between the drugs and different safety outcomes, but it is not a direct test. It helps doctors choose the safer option for people who are more vulnerable.

Who did this work

Yen CL · Li PR · Wu CY · Tsai CY · Chen JJ · Jenq CC · Hsu HH · Kuo CF · See LC · Yang HY

Source

Article · PubMed, the drug frontier · 2026 Oct 19
https://pubmed.ncbi.nlm.nih.gov/42896077/